Pioneers in Neuroscience
At Biogen, our mission is clear: we are pioneers in neuroscience.
The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and SMA types I, II and III.
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.
Biogen is committed to meeting all global transparency requirements. As is our obligation, we record all transfers of value to healthcare professionals and organisations and report in accordance with the applicable local codes and laws.
CO-GBR-0002 Date of preparation: October 2018